On September 14, according to the official website of CDE, AstraZeneca's clinical trial application for the Class 1.1 chemical drug AZD5462 tablets was accepted. According to public information, the drug is a relaxin RXFP1 receptor agonist.
Relaxin, as an agonist of the relaxin 1 receptor (RXFP1), produces unique and diverse biological effects, including pulmonary and systemic vasodilation, tissue remodeling/fibrosis reversal, and reduced inflammation, and therefore also has potential in cardiopulmonary diseases. significant curative effect. In addition, this substance is also known as the "pregnancy hormone" and is regulated during pregnancy to help the expectant mother's cardiovascular system meet the increased demands of the developing fetus and remodel tissue and musculoskeletal structure. .

AZD5462 is a relaxin RXFP1 receptor agonist developed by AstraZeneca. Preclinical studies on monkey models of heart failure with reduced ejection fraction (HFrEF) showed that cardiac systolic function was improved after 8 weeks of treatment. There was no significant increase in mean arterial blood pressure or heart rate. Currently, multiple studies of AZD5462 are ongoing, including clinical studies in patients with chronic heart failure that have reached the Phase IIb stage.
Once the clinical trial application for AZD5462 tablets is successfully approved by the CDE, AstraZeneca may start further research on it in China.

https://news.yaozh.com/archive/44236.html